JP2022537019A5 - - Google Patents

Info

Publication number
JP2022537019A5
JP2022537019A5 JP2021571689A JP2021571689A JP2022537019A5 JP 2022537019 A5 JP2022537019 A5 JP 2022537019A5 JP 2021571689 A JP2021571689 A JP 2021571689A JP 2021571689 A JP2021571689 A JP 2021571689A JP 2022537019 A5 JP2022537019 A5 JP 2022537019A5
Authority
JP
Japan
Prior art keywords
agonist
binding molecule
psma
antigen
bispecific antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537019A (ja
JP7743313B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038786 external-priority patent/WO2020257681A1/en
Publication of JP2022537019A publication Critical patent/JP2022537019A/ja
Publication of JP2022537019A5 publication Critical patent/JP2022537019A5/ja
Priority to JP2024144403A priority Critical patent/JP2024164199A/ja
Application granted granted Critical
Publication of JP7743313B2 publication Critical patent/JP7743313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571689A 2019-06-21 2020-06-19 Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 Active JP7743313B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024144403A JP2024164199A (ja) 2019-06-21 2024-08-26 Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864999P 2019-06-21 2019-06-21
US62/864,999 2019-06-21
PCT/US2020/038786 WO2020257681A1 (en) 2019-06-21 2020-06-19 Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024144403A Division JP2024164199A (ja) 2019-06-21 2024-08-26 Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Publications (3)

Publication Number Publication Date
JP2022537019A JP2022537019A (ja) 2022-08-23
JP2022537019A5 true JP2022537019A5 (cg-RX-API-DMAC10.html) 2023-06-21
JP7743313B2 JP7743313B2 (ja) 2025-09-24

Family

ID=71528054

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571689A Active JP7743313B2 (ja) 2019-06-21 2020-06-19 Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用
JP2024144403A Pending JP2024164199A (ja) 2019-06-21 2024-08-26 Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024144403A Pending JP2024164199A (ja) 2019-06-21 2024-08-26 Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Country Status (12)

Country Link
US (1) US20200399372A1 (cg-RX-API-DMAC10.html)
EP (1) EP3986933A1 (cg-RX-API-DMAC10.html)
JP (2) JP7743313B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220024594A (cg-RX-API-DMAC10.html)
CN (2) CN114025802B (cg-RX-API-DMAC10.html)
AU (1) AU2020296181A1 (cg-RX-API-DMAC10.html)
CA (1) CA3139827A1 (cg-RX-API-DMAC10.html)
IL (1) IL289041A (cg-RX-API-DMAC10.html)
MA (1) MA56515A (cg-RX-API-DMAC10.html)
MX (1) MX2021015271A (cg-RX-API-DMAC10.html)
WO (1) WO2020257681A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202109048B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147784A1 (zh) * 2022-02-07 2023-08-10 江苏恒瑞医药股份有限公司 特异性结合psma和cd3的抗原结合分子及其医药用途
WO2023224912A1 (en) * 2022-05-16 2023-11-23 Regeneron Pharmaceuticals, Inc. Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
JPWO2025070636A1 (cg-RX-API-DMAC10.html) * 2023-09-26 2025-04-03
CN118086511B (zh) * 2024-04-25 2024-07-09 中国中医科学院望京医院(中国中医科学院骨伤科研究所) 胃粘膜肠上皮化生亚型生物标志物folh1及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
HUE050159T2 (hu) * 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
US11033642B2 (en) 2014-03-19 2021-06-15 Universitat Zurich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
CA2949936C (en) * 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
NZ731966A (en) * 2014-10-16 2019-11-29 Univ Melbourne Novel imaging composition and uses thereof
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
RS67792B1 (sr) * 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
JP7125400B2 (ja) * 2016-12-19 2022-08-24 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 標的化4-1bb(cd137)アゴニストとの併用療法
KR102692708B1 (ko) * 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
US10174122B2 (en) * 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
AU2019315440B2 (en) * 2018-07-30 2025-03-13 Angeles Therapeutics, Inc. Improving the efficacy and safety of adoptive cellular therapies

Similar Documents

Publication Publication Date Title
JP2022537269A5 (cg-RX-API-DMAC10.html)
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
JP2022078265A (ja) 肺癌の処置のための抗pd-1抗体
JP2021519076A5 (cg-RX-API-DMAC10.html)
TWI549690B (zh) 包含抗-cd19類美登素(maytansinoid)免疫結合物及利妥昔單抗(rituximab)之用於治療cd19+b-細胞惡性症狀之組合療法
JP2018502120A5 (cg-RX-API-DMAC10.html)
JP2021513844A5 (cg-RX-API-DMAC10.html)
JP2019533475A5 (cg-RX-API-DMAC10.html)
JP2015534577A5 (cg-RX-API-DMAC10.html)
JP2013100314A5 (cg-RX-API-DMAC10.html)
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2022528030A5 (cg-RX-API-DMAC10.html)
WO2009147695A1 (ja) 抗がん剤
JP2022543765A5 (cg-RX-API-DMAC10.html)
JP7851684B2 (ja) Emt経路を遮断してがん幹細胞を克服するil8
JP2024540275A5 (cg-RX-API-DMAC10.html)
JP2025501978A5 (cg-RX-API-DMAC10.html)
JP2023505222A5 (cg-RX-API-DMAC10.html)
JPH06501705A (ja) 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
JP2025515092A5 (cg-RX-API-DMAC10.html)
JP2011505371A5 (cg-RX-API-DMAC10.html)
WO2019214492A1 (zh) 抗her2抗体-药物偶联物在治疗癌症中的用途
Zhou et al. Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies
WO2001052889A1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
RU2021132847A (ru) Применение биспецифических антигенсвязывающих молекул, которые связывают psma и cd3, в комбинации с костимуляцией 4-1bb